efavirenz + emtricitabine + tenofovir disoproxil fumarate + losartan

This is a non-standard, multi-drug combination consisting of three antiretroviral agents—efavirenz, emtricitabine, and tenofovir disoproxil fumarate—plus the antihypertensive agent losartan. - Efavirenz is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that inhibits HIV-1 reverse transcriptase, thereby blocking viral replication[7]. - Emtricitabine and tenofovir disoproxil fumarate are nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), also inhibiting HIV-1 reverse transcriptase by different mechanisms[5][1]. These three drugs are commonly co-formulated as Atripla and used as a complete regimen for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 40 kg[5][3][1]. Losartan is an angiotensin II receptor blocker (ARB) used to treat hypertension, reduce the risk of stroke in patients with high blood pressure and left ventricular hypertrophy, and protect kidney function in type 2 diabetes with nephropathy. It works by blocking angiotensin II receptors on blood vessels, leading to vasodilation and reduced blood pressure[6][8][10].